(0.27%) 5 145.25 points
(0.15%) 38 497 points
(0.44%) 17 924 points
(-0.68%) $83.28
(1.92%) $1.960
(-0.07%) $2 345.50
(-0.15%) $27.50
(2.76%) $947.55
(-0.04%) $0.934
(-0.02%) $11.02
(-0.24%) $0.798
(1.87%) $93.59
Live Chart Being Loaded With Signals
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight...
Stats | |
---|---|
Dagens volum | 372 259 |
Gjennomsnittsvolum | 331 386 |
Markedsverdi | 31.06M |
EPS | €0 ( 2024-04-08 ) |
Neste inntjeningsdato | ( €0 ) 2024-05-15 |
Last Dividend | €0 ( N/A ) |
Next Dividend | €0 ( N/A ) |
P/E | -0.620 |
ATR14 | €0.00700 (1.05%) |
Volum Korrelasjon
Poxel SA Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Poxel SA Korrelasjon - Valuta/Råvare
Poxel SA Økonomi
Annual | 2023 |
Omsetning: | €1.98M |
Bruttogevinst: | €1.98M (100.00 %) |
EPS: | €0 |
FY | 2023 |
Omsetning: | €1.98M |
Bruttogevinst: | €1.98M (100.00 %) |
EPS: | €0 |
FY | 2022 |
Omsetning: | €674 000 |
Bruttogevinst: | €2 000.00 (0.30 %) |
EPS: | €-1.080 |
FY | 2021 |
Omsetning: | €13.40M |
Bruttogevinst: | €13.34M (99.56 %) |
EPS: | €-0.830 |
Financial Reports:
No articles found.
Poxel SA
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is Imeglimin, an oral drug candidate, which completed Phase III clinical development stage in Japan, as well as in Phase III in the United States and Europe for the treatment of type 2 diabetes that improves pancreatic beta cell function, reduces insulin resistance, and decreases cardiovascular and metabolic disease risk factors, such as heightened blood lipid levels and excess body weight. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH). The company has a licensing agreement with Enyo Pharma S.A.S. for the development of PXL007 (EYP001), a synthetic non-steroidal and non-bile acid FXR agonist that is in Phase II study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial pyruvate carrier inhibitor, which is in a phase I clinical trial for the treatment of NASH. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.